Diagnosis and Treatment of Osteoporosis in Chronic Renal Disease

Seminars in Nephrology

Volumn 29, Issue 2, 2009, Pages 144-155

  Miller, Paul D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

bisphosphonates; bone biopsy; bone mineral density; chronic kidney disease; CKD MBD; dual energy x ray absorptiometry; fragility fractures; Osteoporosis; osteoporosis treatments; raloxifene; teriparatide; World Health Organization

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE FRAGILITY; BONE METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; HUMAN; KIDNEY FUNCTION; MORPHOMETRICS; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; VITAMIN SUPPLEMENTATION; WORLD HEALTH ORGANIZATION;

ABSORPTIOMETRY, PHOTON; BIOPSY; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY FAILURE, CHRONIC; OSTEOPOROSIS; PROGNOSIS;

EID: 64049106584     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2009.01.007     Document Type: Article

References (60)

1. Melton III L.J. Epidemiology worldwide. Endocrinol Metab Clin North Am 32 (2003) 1-13 v
2. Burge R., Dawson-Hughes B., Solomon D.H., et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22 (2007) 465-475
3. Barrett-Connor E., Siris E.S., Wehren L.E., Miller P.D., Abbott T.A., Berger M.L., et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 20 (2005) 185-194
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843 (1994) 1-129
5. Miller P.D., and Bonnick S.L. Clinical utilization of bone mass measurements for the assessment and management of osteoporosis in the adult population. In: Favus M. (Ed). Primer of metabolic bone diseases (1999), American Society for Bone and Mineral Research, Washington DC 152-159
6. Nickolas T.L., Leonard M.B., and Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2 (2008) 1-11
7. Gal-Moscovici A., and Sprague S.M. Osteoporosis and chronic kidney disease. Semin Dial 20 (2007) 423-430
8. Parfitt A.M., Drezner M., Glorieux F., Kanis J., Malluche H., Meunier P., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2 (1987) 595-610
9. Massry S.G., and Coburn J.W. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 Suppl 3 (2003) S10-S135
10. Andress D.L., and Sherrard D.J. The osteodystrophy of chronic renal failure. In: Schrier R.W. (Ed). Diseases of the kidney and urinary tract (2003), Lippincott Williams and Wilkins, Philadelphia 2735-2768
11. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69 (2006) 1945-1953
12. NIH Consensus Development Panel. Osteoporosis prevention diagnosis and therapy. JAMA 285 (2001)
13. Baim S., Binkley N., Bilezikian J.P., Kendler D., Hans D., Lewiecki E.M., et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 11 (2008) 75-91
14. Siris E., Miller P., Barrett-Connor E., Faulkner K., Wehren L., Abbott T., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). JAMA 286 (2001) 2815-2822
15. Schuit S.C.E., Oei H.H., Witteman J.C., Geurts van Kessel C.H., van Meurs J.B., Nijhuis R., et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34 (2004) 195-202
16. Bouxsein M.L. Non-invasive measurements of bone strength: promise and peril. J Musculoskelet Neuronal Interact 4 (2004) 404-405
17. Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab 26 (2008) 1-8
18. Moe S., Drueke T., and Working Group of the Kidney Disease Improving Global Outcome. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease related mineral and bone disorders (CKD-MBD). Clin J Am Soc Nephrol 3 (2008) 5124-5130
19. Alem A.M., Sherrard D.J., Gillen D.L., et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58 (2000) 396-399
20. Ball A.M., Gillen D.L., Sherrard D., et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288 (2002) 3014-3018
21. Jadoul M., Albert J.M., Akiba T., et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70 (2006) 1358-1366
22. Stehman-Breen C.O., Sherrard D.J., Alem A.M., et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58 (2000) 2200-2205
23. Wehrli F.W., Leonard M.B., Saha P.K., et al. Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone. J Magn Reson Imaging 20 (2004) 83-89
24. Genant H.K., Lang T.F., Engelke K., et al. Advances in the noninvasive assessment of bone density, quality, and structure. Calcif Tissue Int 59 Suppl 1 (1996) S10-S15
25. Roschger P., Paschalis E.P., Fratzl P., and Klaushofer K. Bone mineralization density distribution in health and disease. Bone 42 (2008) 456-466
26. Frost H.M. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 3 (1969) 211-237
27. Hitt O., Jaworski Z.F., Shimizu A.G., and Frost H.M. Tissue-level bone formation rates in chronic renal failure, measured by means of tetracycline bone labeling. Can J Physiol Pharmacol 48 (1970) 824-828
28. Coen G. Adynamic bone disease: an update. J Nephrol 18 (2005) 117-122
29. Parfitt A.M. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 12 (2003) 387-403
30. Brandenburg V.M., and Floege J. Adynamic bone disease-bone and beyond. Nephrol Dial Transplant 3 (2008) 135-147
31. Hruska K.A., Saab G., Mathew S., and Lund R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 20 (2007) 309-315
32. Miller P.D., Hochberg M.C., Wehren L.E., Ross P.D., and Wasnich R.D. How useful are measures of BMD and bone turnover?. Curr Med Res Opin 21 (2005) 545-553
33. Miller P.D. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporosis Rep 3 (2005) 103-110
34. Chavassieux P.M., and Delmas P.D. Bone remodeling: biochemical markers or bone biopsy?. J Bone Miner Res 21 (2006) 178-179
35. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 12 (2008) 157-170
36. Hochberg M., Greenspan S., Wasnich R., Miller P., Thompson D., and Ross P. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87 (2002) 1586-1592
37. Bouxsein M.L., and Delmas P.D. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 23 (2008) 1155-1167
38. Chen P., Satterwhite J.H., Licatta A.A., Lewiecki E.M., Sipos A.A., Miskurski D.M., et al. Early changes in biochemical markers of bone formation predict the BMD response with teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20 (2005) 962-970
39. Miller P.D., Delmas P.D., Lindsay R., Watts N.B., Luckey M., Adachi J., et al. Early responsiveness of women with osteoporosis to teriparatide following therapy with alendronate or risedronate. J Clin Endocrinol Metab 93 (2008) 3785-3793
40. Miller P.D., and Lerma E.V. Renal bone diseases. In: Kleerekoper M., Siris E., and McClung M. (Eds). the bone and mineral manual-a practical guide. 2nd ed. (2005), Elsevier Academic Press, Burlington, MA
41. Miller P.D. Is there a role for bisphosphonates in patients with stage 5 chronic kidney disease?. Semin Dial 20 (2007) 191-197
42. Miller P.D. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R., Feldman D., Nelson D.A., and Rosen C.J. (Eds). Osteoporosis. 3rd ed. (2007), Elsevier Academic Press, San Diego, CA 1725-1736
43. Russell R.G., Watts N.B., Ebetino F.H., and Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int (2008)
44. Dawson-Hughes B., and Bischoff-Ferrari H.A. Therapy of osteoporosis with calcium and vitamin D. J Bone Miner Res 22 Suppl 2 (2007) V59-V63
45. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18 (2007) 1033-1046
46. Dawson-Hughes B., Tosteson A.N., Melton III L.J., Baim S., Favus M., Khossla S., et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19 (2008) 449-458
47. Eisman J.A., Civetelli R., Adami S., Czerwinski E., Recknor C., Prince R., et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35 (2008) 488-497
48. Black D.M., Delmas P.D., Eastell R.R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
49. Lewiecki E.M., and Miller P.D. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 6 (2007) 663-672
50. Perazella M.A., and Markowitz G.S. Bisphosphonate nephrotoxicity. Kidney Int (2008)
51. Boonen S., Sellmeyer D.E., Lippuner K., Orlov-Morozov A., Abrams K., Messenbrink P., et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74 (2008) 641-648
52. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.A., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
53. Miller P.D., Schwartz E.N., Chen P., Misurski D.A., and Krege J.H. Teriparatide in postmenopausal women with osteoporosis and impaired renal function. Osteoporosis Int 18 (2007) 59-68
54. Miller P.D., Roux C., Boonen S., Barton I., Dunlap L., and Burgio D. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20 (2005) 2015-2115
55. Jamal S.A., Bauer D.C., Ensrud K.E., Cauley J.A., Hochberg M., Ishani A., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22 (2007) 503-508
56. Ishani A., Blackwell T., Jamal S.A., Cummings S.R., Ensrud K.E., and MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 19 (2008) 1430-1438
57. Miller P.D. The role of bone biopsy in chronic renal failure. Clin J Am Soc Nephrol 3 (2008) 5140-5151
58. Ferreira M.A. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. Nephrol Dial Transplant 15 Suppl 5 (2000) 8-14
59. Trueba D., Sawaya B.P., Mawad H., and Malluche H.H. Bone biopsy: indications, techniques, and complications. Semin Dial 16 (2003) 341-345
60. Miller P.D., and Shane E. Management of transplantation renal bone disease: Interplay of bone mineral density and decision regarding bisphosphonate use. In: Weir M.R. (Ed). Medical management of kidney transplantation (2005), Lippincott Williams and Wilkins, Baltimore 359-375